Sequencing and re-expressing B cell receptors from lymphoma tissue of rheumatoid arthritis patients reveals polyreactive and ...

Stanford's Richard Lafayette discusses 36-week povetacicept data in IgA nephropathy, including proteinuria, hematuria, and safety findings. Povetacicept, a dual inhibitor of B-cell activating factor ...

Artiva Biotherapeutics Inc. ARTV announced it will halt further clinical development of its lead cell therapy candidate, ...

A small longitudinal study of 12 transplant recipients found that two-dimensional B-cell receptor analysis revealed ...

Patients who develop cytokine release syndrome after chimeric antigen receptor T-cell therapy for autoimmune disease ...

When treatment is urgent, are there clues to foresee the outcome?When you are told of a relapse and must start the next treatment as soon as possible, the first thing many people want to know is, ...

Shanghai Junshi Biosciences Co., Ltd. announced that the first patient dosing has been completed in a randomized, open-label, multicenter phase 3 clinical study of the company?s product, a recombinant ...

Shanghai Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ...

Four CD20xCD3 T-cell engagers post strikingly similar response rates in B-cell lymphoma, yet one remains EU-approved and US-blocked. Here's what actually distinguishes them.

Identify cost-efficient trial locations, investment opportunities and enrollment trends to sharpen strategy and gain a competitive advantage.Dublin, Oct. (GLOBE NEWSWIRE) -- "Diffuse Large B-Cell ...

Children with B-cell acute lymphoblastic leukemia may experience adverse family outcomes related to household changes and family functioning.